COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Postmarketing Surveillance Study With MOBEC®

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02182726
Recruitment Status : Completed
First Posted : July 8, 2014
Last Update Posted : July 9, 2014
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:

The aim of the study is to investigate

  • the indication for MOBEC in a dose of 15 mg per day
  • the treatments patients were receiving before switching to 15 mg MOBEC
  • how treatment with 15 mg is assessed compared with previous treatment
  • how effective and safe treatment with 15 mg MOBEC is considered

Condition or disease Intervention/treatment
Osteoarthritis Drug: MOBEC

Layout table for study information
Study Type : Observational
Actual Enrollment : 4760 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: COX-2 Postmarketing Surveillance Study With MOBEC® 15 mg Tablets
Study Start Date : May 2001
Actual Primary Completion Date : December 2001

Resource links provided by the National Library of Medicine

Drug Information available for: Meloxicam

Group/Cohort Intervention/treatment

Primary Outcome Measures :
  1. Nature and incidence of adverse drug reactions (ADR) [ Time Frame: up to week 8 ]
  2. Assessment of efficacy by physician on a 5-point scale [ Time Frame: up to week 8 ]
  3. Assessment of tolerability by physician on a 5-point scale [ Time Frame: up to week 8 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
primarily internal and general medical practices

Inclusion Criteria:

  • An indication for a treatment with 15 mg MOBEC of at least four weeks

    • the symptomatic short-term treatment of osteoarthritis
    • the symptomatic long-term treatment of rheumatoid arthritis (chronic polyarthritis); restriction: the recommended dose for long-term treatment of elderly patients is 7.5 mg)
    • the symptomatic treatment of ankylosing spondylitis

Exclusion Criteria:

  • Treatment with MOBEC prior to the start of the study
  • Patients with any of the general or specific contraindications of MOBEC

Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT02182726    
Other Study ID Numbers: 107.245
First Posted: July 8, 2014    Key Record Dates
Last Update Posted: July 9, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action